- Home
- AIRS vs ZNTL Comparison
AIRS vs ZNTL Comparison
Compare AIRS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- ZNTL
- Stock Information
- Founded
- AIRS 2012
- ZNTL 2014
- Country
- AIRS United States
- ZNTL United States
- Employees
- AIRS N/A
- ZNTL N/A
- Industry
- AIRS Medical/Nursing Services
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- ZNTL Health Care
- Exchange
- AIRS Nasdaq
- ZNTL Nasdaq
- Market Cap
- AIRS 334.6M
- ZNTL 273.1M
- IPO Year
- AIRS 2021
- ZNTL 2020
- Fundamental
- Price
- AIRS $7.00
- ZNTL $3.23
- Analyst Decision
- AIRS Hold
- ZNTL Buy
- Analyst Count
- AIRS 3
- ZNTL 8
- Target Price
- AIRS $5.50
- ZNTL $10.50
- AVG Volume (30 Days)
- AIRS 227.4K
- ZNTL 1.6M
- Earning Date
- AIRS 11-08-2024
- ZNTL 11-12-2024
- Dividend Yield
- AIRS N/A
- ZNTL N/A
- EPS Growth
- AIRS N/A
- ZNTL N/A
- EPS
- AIRS N/A
- ZNTL N/A
- Revenue
- AIRS $188,780,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- AIRS N/A
- ZNTL N/A
- Revenue Next Year
- AIRS $11.17
- ZNTL N/A
- P/E Ratio
- AIRS N/A
- ZNTL N/A
- Revenue Growth
- AIRS N/A
- ZNTL N/A
- 52 Week Low
- AIRS $2.92
- ZNTL $2.66
- 52 Week High
- AIRS $9.20
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- AIRS 55.11
- ZNTL 46.44
- Support Level
- AIRS $5.54
- ZNTL $2.90
- Resistance Level
- AIRS $9.20
- ZNTL $4.44
- Average True Range (ATR)
- AIRS 0.71
- ZNTL 0.37
- MACD
- AIRS -0.12
- ZNTL -0.06
- Stochastic Oscillator
- AIRS 39.89
- ZNTL 21.43
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.